DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Phase 2

Recruiting

Conditions: Stage IV Renal Cell Cancer AJCC v8
Metastatic Papillary Renal Cell Carcinoma

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging

First Posted Date: 2022-06-09

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200

Registration Number: NCT05411081

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 195 locations

A Natural History Study of Metabolic Sizing in Health and Disease

Recruiting

Conditions: Metabolic Disorders
Normal Physiology
Chronic Kidney Disease
Diabetes
Cancer

First Posted Date: 2022-06-01

Last Posted Date: 2025-03-26

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 2000

Registration Number: NCT05398783

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1

Recruiting

Conditions: Diffuse Large Cell Lymphoma
Non-Hodgkin Lymphoma
Burkitt Lymphoma
Plasmablastic Lymphoma
B-Cell Neoplasm

Interventions: Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin
Drug: Etoposide
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2022-05-25

Last Posted Date: 2025-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT05389423

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Phase 1

Withdrawn

Conditions: Malignant Pleural Mesotheliomas (Mpm)
Malignant Pleural Effusions (Mpe)
Epithelial Tumors, Malignant
Mesothelin (Msln)
Pleural Effusions, Malignant

Interventions: Procedure: Cytoreductive surgery
Drug: LMB-100
Diagnostic Test: Immunohistochemical Assay for Mesothelin

First Posted Date: 2022-05-17

Last Posted Date: 2024-02-02

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05375825

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Phase 1

Recruiting

Conditions: Breast Carcinoma
Malignant Solid Neoplasm

Interventions: Drug: Abemaciclib
Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Diagnostic Imaging Testing

First Posted Date: 2022-05-13

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05372640

Locations: 🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 4 locations

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: Neratinib Maleate
Biological: Trastuzumab Deruxtecan

First Posted Date: 2022-05-13

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05372614

Locations: 🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 15 locations

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma
NHL
Hematologic Malignancies
Lymphoid Malignancies
Lymphoma

Interventions: Device: Vysis LSI MYC Break Apart Rearrangement Probe Kit
Drug: Venetoclax
Drug: VIP152
Drug: Prednisone
Diagnostic Test: PET
Diagnostic Test: EKG
Diagnostic Test: ECHO
Diagnostic Test: CT neck chest, abdomen, and pelvis
Diagnostic Test: MRI
Procedure: Bone marrow aspiration/Biopsy

First Posted Date: 2022-05-12

Last Posted Date: 2025-04-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT05371054

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

Not Applicable

Recruiting

Conditions: Legius Syndrome
Cardiofaciocutaneous Syndrome
Neurofibromatosis 1
Noonan Syndrome
Costello Syndrome

Interventions: Behavioral: Waitlist
Behavioral: ACT Intervention

First Posted Date: 2022-05-05

Last Posted Date: 2025-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT05361811

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Phase 2

Recruiting

Conditions: Cancer Of Prostate

Interventions: Drug: M9241
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2022-05-05

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT05361798

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Extensive Stage Lung Small Cell Carcinoma
Limited Stage Lung Small Cell Carcinoma
Recurrent Lung Small Cell Carcinoma
Platinum-Resistant Lung Small Cell Carcinoma
Platinum-Sensitive Lung Small Cell Carcinoma
Recurrent Extensive Stage Lung Small Cell Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Pembrolizumab
Drug: Tazemetostat Hydrobromide
Drug: Topotecan Hydrochloride

First Posted Date: 2022-04-29

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT05353439

Locations: 🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy